PDF(Pubmed)
Abstract：
Nanoliposomes are nano-sized vesicles that can be used as drug delivery carriers with the ability to encapsulate both hydrophobic and hydrophilic compounds. Moreover, their lipid compositions facilitate their internalization by cells. However, the interaction between nanoliposomes and the membrane barrier of the human body is not well-known. If cellular tests and animal testing offer a solution, their lack of physiological relevance and ethical concerns make them unsuitable to properly mimic human body complexity. Microfluidics, which allows the environment of the human body to be imitated in a controlled way, can fulfil this role. However, existing models are missing the presence of something that would mimic a basal membrane, often consisting of a simple cell layer on a polymer membrane. In this study, we investigated the diffusion of nanoliposomes in a microfluidic system and found the optimal parameters to maximize their diffusion. Then, we incorporated a custom made GelMA with a controlled degree of substitution and studied the passage of fluorescently labeled nanoliposomes through this barrier. Our results show that highly substituted GelMA was more porous than lower substitution GelMA. Overall, our work lays the foundation for the incorporation of a hydrogel mimicking a basal membrane on a drug delivery microfluidic platform.
摘要：
纳米脂质体是纳米大小的囊泡,其可用作药物递送载体,具有包封疏水性和亲水性化合物的能力。此外，它们的脂质组成促进它们被细胞内化。然而,纳米脂质体与人体膜屏障之间的相互作用尚不为人所知。如果细胞测试和动物测试提供解决方案，他们缺乏生理相关性和伦理问题，使他们不适合适当地模仿人体的复杂性。微流体,允许以受控的方式模仿人体的环境，可以发挥这一作用。然而,现有的模型缺少模仿基底膜的东西，通常由聚合物膜上的简单细胞层组成。在这项研究中,我们研究了纳米脂质体在微流体系统中的扩散，并找到了使其扩散最大化的最佳参数。然后，我们结合了定制的具有受控取代度的GelMA，并研究了荧光标记的纳米脂质体通过该屏障的通道。我们的结果表明,高度取代的GelMA比低取代的GelMA更多孔。总的来说,我们的工作为在药物递送微流体平台上引入模拟基底膜的水凝胶奠定了基础.
